Pancreatic cancer cells were subsequently treated with downregulated MACC1-AS1 or STK33 using AKT-IN-9 (an Akt inhibitor), Nrf2-IN-1 (an NRF2 inhibitor), JSH-23 (an NF-κB inhibitor), SB203580 (a p38 inhibitor), SP600125 (a JNK inhibitor), and SCH772984 (an ERK inhibitor). Here, NFKB1 is linked to familial pancreatic carcinoma.